History in perspective: How Alzheimer's Disease came to be where it is?

•Core pathological features of AD include deposition of Aβ plaques and tau tangles.•Significant crosstalk is observed between the etiological hypotheses of AD.•2018 research framework has updated the definition of AD to a molecular construct.•Shift in research towards early diagnosis of AD through b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain research 2021-05, Vol.1758, p.147342-147342, Article 147342
Hauptverfasser: Ahmed, Tehniat F., Ahmed, Affan, Imtiaz, Fauzia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 147342
container_issue
container_start_page 147342
container_title Brain research
container_volume 1758
creator Ahmed, Tehniat F.
Ahmed, Affan
Imtiaz, Fauzia
description •Core pathological features of AD include deposition of Aβ plaques and tau tangles.•Significant crosstalk is observed between the etiological hypotheses of AD.•2018 research framework has updated the definition of AD to a molecular construct.•Shift in research towards early diagnosis of AD through blood-based biomarkers.•Targeting individual pathological pathways has yielded no therapeutic success. Treatment of Alzheimer’s Disease (AD) remains an unsolved issue despite the pronounced global attention it has received from researchers over the last four decades. Determining the primary cause of the disease is challenging due to its long prodromal phase and multifactorial etiology. Regardless, academic disagreements amongst the scientific community have helped in making significant advancements in underpinning the molecular basis of disease pathogenesis. Substantial development in fluid and imaging biomarkers for AD led to a sharp turn in defining the disease as a molecular construct, dispensing its clinical definition. With conceptual progress, revisions in the diagnostic criteria of AD were made, culminating into the research framework proposed by National Institute on Aging and Alzheimer’s Association in 2018 which unified different stages of the disease continuum, giving a common language of AT(N)11AT(N): Amyloid-β biomarkers, Pathologic tau biomarkers, Neurodegenerative/Neuronal injury biomarkers. classification to researchers. With realization that dementia is the final stage of AD spectrum, its early diagnosis by means of cerebrospinal fluid biomarkers, Positron Emission Tomography and Magnetic Resonance Imaging of the brain holds crucial importance in discovering ways of halting the disease progression. This article maps the insights into the pathogenesis as well as the diagnostic criteria and tests for AD as these have evolved over time. A contextualized timeline of how the understanding of AD has matured with advancing knowledge allows future research to be directed and unexplored avenues to be prioritized.
doi_str_mv 10.1016/j.brainres.2021.147342
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2487435168</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006899321000676</els_id><sourcerecordid>2487435168</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-ef7d236eceb9c89f129b3223755ff1cd65aa2da8a1bcbb1370c90d131b2893e13</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EoqXwC5V3sEnwI3EcNlAVaJEqsYG1ZTsT1VXTBDttVb6eVKFsWY1GOneu5iA0piSmhIr7VWy8dhsPIWaE0ZgmGU_YGRpSmbFIsIScoyEhREQyz_kAXYWw6lbOc3KJBpyniWRCDtFs7kJb-wN2G9yADw3Y1u3gAc_rPZ6sv5fgKvC3AT-7ADoAtroC3NbYAN4vwQN2LXbh8RpdlHod4OZ3jtDn68vHdB4t3mdv08kislzINoIyKxgXYMHkVuYlZbnhjPEsTcuS2kKkWrNCS02NNYbyjNicFJRTw2TOgfIRuuvvNr7-2kJoVeWChfVab6DeBsUSmSU8pUJ2qOhR6-sQPJSq8a7S_qAoUUeJaqVOEtVRouoldsHxb8fWVFD8xU7WOuCpB6D7dOfAq2AdbCwUznf-VFG7_zp-AJeMhYw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2487435168</pqid></control><display><type>article</type><title>History in perspective: How Alzheimer's Disease came to be where it is?</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Ahmed, Tehniat F. ; Ahmed, Affan ; Imtiaz, Fauzia</creator><creatorcontrib>Ahmed, Tehniat F. ; Ahmed, Affan ; Imtiaz, Fauzia</creatorcontrib><description>•Core pathological features of AD include deposition of Aβ plaques and tau tangles.•Significant crosstalk is observed between the etiological hypotheses of AD.•2018 research framework has updated the definition of AD to a molecular construct.•Shift in research towards early diagnosis of AD through blood-based biomarkers.•Targeting individual pathological pathways has yielded no therapeutic success. Treatment of Alzheimer’s Disease (AD) remains an unsolved issue despite the pronounced global attention it has received from researchers over the last four decades. Determining the primary cause of the disease is challenging due to its long prodromal phase and multifactorial etiology. Regardless, academic disagreements amongst the scientific community have helped in making significant advancements in underpinning the molecular basis of disease pathogenesis. Substantial development in fluid and imaging biomarkers for AD led to a sharp turn in defining the disease as a molecular construct, dispensing its clinical definition. With conceptual progress, revisions in the diagnostic criteria of AD were made, culminating into the research framework proposed by National Institute on Aging and Alzheimer’s Association in 2018 which unified different stages of the disease continuum, giving a common language of AT(N)11AT(N): Amyloid-β biomarkers, Pathologic tau biomarkers, Neurodegenerative/Neuronal injury biomarkers. classification to researchers. With realization that dementia is the final stage of AD spectrum, its early diagnosis by means of cerebrospinal fluid biomarkers, Positron Emission Tomography and Magnetic Resonance Imaging of the brain holds crucial importance in discovering ways of halting the disease progression. This article maps the insights into the pathogenesis as well as the diagnostic criteria and tests for AD as these have evolved over time. A contextualized timeline of how the understanding of AD has matured with advancing knowledge allows future research to be directed and unexplored avenues to be prioritized.</description><identifier>ISSN: 0006-8993</identifier><identifier>EISSN: 1872-6240</identifier><identifier>DOI: 10.1016/j.brainres.2021.147342</identifier><identifier>PMID: 33548268</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Alzheimer Disease - history ; Alzheimer’s Disease ; Biomarkers ; Diagnosis ; History ; History, 20th Century ; History, 21st Century ; Humans ; Neurodegenerative dementia ; Pathogenesis</subject><ispartof>Brain research, 2021-05, Vol.1758, p.147342-147342, Article 147342</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-ef7d236eceb9c89f129b3223755ff1cd65aa2da8a1bcbb1370c90d131b2893e13</citedby><cites>FETCH-LOGICAL-c368t-ef7d236eceb9c89f129b3223755ff1cd65aa2da8a1bcbb1370c90d131b2893e13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.brainres.2021.147342$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33548268$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ahmed, Tehniat F.</creatorcontrib><creatorcontrib>Ahmed, Affan</creatorcontrib><creatorcontrib>Imtiaz, Fauzia</creatorcontrib><title>History in perspective: How Alzheimer's Disease came to be where it is?</title><title>Brain research</title><addtitle>Brain Res</addtitle><description>•Core pathological features of AD include deposition of Aβ plaques and tau tangles.•Significant crosstalk is observed between the etiological hypotheses of AD.•2018 research framework has updated the definition of AD to a molecular construct.•Shift in research towards early diagnosis of AD through blood-based biomarkers.•Targeting individual pathological pathways has yielded no therapeutic success. Treatment of Alzheimer’s Disease (AD) remains an unsolved issue despite the pronounced global attention it has received from researchers over the last four decades. Determining the primary cause of the disease is challenging due to its long prodromal phase and multifactorial etiology. Regardless, academic disagreements amongst the scientific community have helped in making significant advancements in underpinning the molecular basis of disease pathogenesis. Substantial development in fluid and imaging biomarkers for AD led to a sharp turn in defining the disease as a molecular construct, dispensing its clinical definition. With conceptual progress, revisions in the diagnostic criteria of AD were made, culminating into the research framework proposed by National Institute on Aging and Alzheimer’s Association in 2018 which unified different stages of the disease continuum, giving a common language of AT(N)11AT(N): Amyloid-β biomarkers, Pathologic tau biomarkers, Neurodegenerative/Neuronal injury biomarkers. classification to researchers. With realization that dementia is the final stage of AD spectrum, its early diagnosis by means of cerebrospinal fluid biomarkers, Positron Emission Tomography and Magnetic Resonance Imaging of the brain holds crucial importance in discovering ways of halting the disease progression. This article maps the insights into the pathogenesis as well as the diagnostic criteria and tests for AD as these have evolved over time. A contextualized timeline of how the understanding of AD has matured with advancing knowledge allows future research to be directed and unexplored avenues to be prioritized.</description><subject>Alzheimer Disease - history</subject><subject>Alzheimer’s Disease</subject><subject>Biomarkers</subject><subject>Diagnosis</subject><subject>History</subject><subject>History, 20th Century</subject><subject>History, 21st Century</subject><subject>Humans</subject><subject>Neurodegenerative dementia</subject><subject>Pathogenesis</subject><issn>0006-8993</issn><issn>1872-6240</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtOwzAQRS0EoqXwC5V3sEnwI3EcNlAVaJEqsYG1ZTsT1VXTBDttVb6eVKFsWY1GOneu5iA0piSmhIr7VWy8dhsPIWaE0ZgmGU_YGRpSmbFIsIScoyEhREQyz_kAXYWw6lbOc3KJBpyniWRCDtFs7kJb-wN2G9yADw3Y1u3gAc_rPZ6sv5fgKvC3AT-7ADoAtroC3NbYAN4vwQN2LXbh8RpdlHod4OZ3jtDn68vHdB4t3mdv08kislzINoIyKxgXYMHkVuYlZbnhjPEsTcuS2kKkWrNCS02NNYbyjNicFJRTw2TOgfIRuuvvNr7-2kJoVeWChfVab6DeBsUSmSU8pUJ2qOhR6-sQPJSq8a7S_qAoUUeJaqVOEtVRouoldsHxb8fWVFD8xU7WOuCpB6D7dOfAq2AdbCwUznf-VFG7_zp-AJeMhYw</recordid><startdate>20210501</startdate><enddate>20210501</enddate><creator>Ahmed, Tehniat F.</creator><creator>Ahmed, Affan</creator><creator>Imtiaz, Fauzia</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210501</creationdate><title>History in perspective: How Alzheimer's Disease came to be where it is?</title><author>Ahmed, Tehniat F. ; Ahmed, Affan ; Imtiaz, Fauzia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-ef7d236eceb9c89f129b3223755ff1cd65aa2da8a1bcbb1370c90d131b2893e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alzheimer Disease - history</topic><topic>Alzheimer’s Disease</topic><topic>Biomarkers</topic><topic>Diagnosis</topic><topic>History</topic><topic>History, 20th Century</topic><topic>History, 21st Century</topic><topic>Humans</topic><topic>Neurodegenerative dementia</topic><topic>Pathogenesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ahmed, Tehniat F.</creatorcontrib><creatorcontrib>Ahmed, Affan</creatorcontrib><creatorcontrib>Imtiaz, Fauzia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ahmed, Tehniat F.</au><au>Ahmed, Affan</au><au>Imtiaz, Fauzia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>History in perspective: How Alzheimer's Disease came to be where it is?</atitle><jtitle>Brain research</jtitle><addtitle>Brain Res</addtitle><date>2021-05-01</date><risdate>2021</risdate><volume>1758</volume><spage>147342</spage><epage>147342</epage><pages>147342-147342</pages><artnum>147342</artnum><issn>0006-8993</issn><eissn>1872-6240</eissn><abstract>•Core pathological features of AD include deposition of Aβ plaques and tau tangles.•Significant crosstalk is observed between the etiological hypotheses of AD.•2018 research framework has updated the definition of AD to a molecular construct.•Shift in research towards early diagnosis of AD through blood-based biomarkers.•Targeting individual pathological pathways has yielded no therapeutic success. Treatment of Alzheimer’s Disease (AD) remains an unsolved issue despite the pronounced global attention it has received from researchers over the last four decades. Determining the primary cause of the disease is challenging due to its long prodromal phase and multifactorial etiology. Regardless, academic disagreements amongst the scientific community have helped in making significant advancements in underpinning the molecular basis of disease pathogenesis. Substantial development in fluid and imaging biomarkers for AD led to a sharp turn in defining the disease as a molecular construct, dispensing its clinical definition. With conceptual progress, revisions in the diagnostic criteria of AD were made, culminating into the research framework proposed by National Institute on Aging and Alzheimer’s Association in 2018 which unified different stages of the disease continuum, giving a common language of AT(N)11AT(N): Amyloid-β biomarkers, Pathologic tau biomarkers, Neurodegenerative/Neuronal injury biomarkers. classification to researchers. With realization that dementia is the final stage of AD spectrum, its early diagnosis by means of cerebrospinal fluid biomarkers, Positron Emission Tomography and Magnetic Resonance Imaging of the brain holds crucial importance in discovering ways of halting the disease progression. This article maps the insights into the pathogenesis as well as the diagnostic criteria and tests for AD as these have evolved over time. A contextualized timeline of how the understanding of AD has matured with advancing knowledge allows future research to be directed and unexplored avenues to be prioritized.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33548268</pmid><doi>10.1016/j.brainres.2021.147342</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0006-8993
ispartof Brain research, 2021-05, Vol.1758, p.147342-147342, Article 147342
issn 0006-8993
1872-6240
language eng
recordid cdi_proquest_miscellaneous_2487435168
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Alzheimer Disease - history
Alzheimer’s Disease
Biomarkers
Diagnosis
History
History, 20th Century
History, 21st Century
Humans
Neurodegenerative dementia
Pathogenesis
title History in perspective: How Alzheimer's Disease came to be where it is?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T22%3A31%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=History%20in%20perspective:%20How%20Alzheimer's%20Disease%20came%20to%20be%20where%20it%20is?&rft.jtitle=Brain%20research&rft.au=Ahmed,%20Tehniat%20F.&rft.date=2021-05-01&rft.volume=1758&rft.spage=147342&rft.epage=147342&rft.pages=147342-147342&rft.artnum=147342&rft.issn=0006-8993&rft.eissn=1872-6240&rft_id=info:doi/10.1016/j.brainres.2021.147342&rft_dat=%3Cproquest_cross%3E2487435168%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2487435168&rft_id=info:pmid/33548268&rft_els_id=S0006899321000676&rfr_iscdi=true